Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer

• Main Authors: Masafumi Yasunaga (Author), Hideaki Yahata (Author), Kaoru Okugawa (Author), Mototsugu Shimokawa (Author), Yumiko Maeda (Author), Emiko Hori (Author), Keisuke Kodama (Author), Hiroshi Yagi (Author), Tatsuhiro Ohgami (Author), Ichiro Onoyama (Author), Kazuo Asanoma (Author), Kiyoko Kato (Author)
• Format: Knjiga
• Izdano: Elsevier, 2022-09-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Objective: Recent randomized phase III trial has shown significant benefit in overall survival (OS) for patients with advanced cervical cancer by adding bevacizumab to conventional chemotherapy. The aim of this study was to evaluate the prognostic impact for Japanese recurrent, persistent, or metast...